Overview
SOPHiA GENETICS built a platform that enables hospitals and clinical labs to analyze genomic data and derive actionable clinical insights. The platform is used for oncology diagnostics, rare disease identification, and pharmacogenomics across a global hospital network.
The company has a dual Belgian and Swiss identity, reflecting its founding roots and operational base. Alychlo, the investment vehicle of Marc Coucke, holds a position in the company. SOPHiA GENETICS is publicly traded, making it one of the Belgian ecosystem's notable public market outcomes in the life sciences and AI intersection.
Key people
Backers
- AAlychlo
Marc Coucke's family office, investing across tech, pharma, and food from a base in Merelbeke.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.